Cargando…

Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users

Background and Objectives: Hepatitis C virus (HCV) is a major cause of liver disease worldwide. People who inject drugs (PWIDs) constitute the majority of patients with HCV infection in the United States and Central Asia. There are several obstacles to treating HCV infection in PWIDs because PWIDs a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Jui-Ting, Hsu, Ping-I, Shie, Chang-Bih, Chuah, Seng-Kee, Wu, I-Ting, Huang, Wen-Wei, Tang, Sheng-Yeh, Tsai, Kun-Feng, Kuo, Li-Fu, Ghose, Supratip, Hsu, Jui-Che, Shih, Chih-An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950806/
https://www.ncbi.nlm.nih.gov/pubmed/35334612
http://dx.doi.org/10.3390/medicina58030436
_version_ 1784675231453937664
author Hsu, Jui-Ting
Hsu, Ping-I
Shie, Chang-Bih
Chuah, Seng-Kee
Wu, I-Ting
Huang, Wen-Wei
Tang, Sheng-Yeh
Tsai, Kun-Feng
Kuo, Li-Fu
Ghose, Supratip
Hsu, Jui-Che
Shih, Chih-An
author_facet Hsu, Jui-Ting
Hsu, Ping-I
Shie, Chang-Bih
Chuah, Seng-Kee
Wu, I-Ting
Huang, Wen-Wei
Tang, Sheng-Yeh
Tsai, Kun-Feng
Kuo, Li-Fu
Ghose, Supratip
Hsu, Jui-Che
Shih, Chih-An
author_sort Hsu, Jui-Ting
collection PubMed
description Background and Objectives: Hepatitis C virus (HCV) is a major cause of liver disease worldwide. People who inject drugs (PWIDs) constitute the majority of patients with HCV infection in the United States and Central Asia. There are several obstacles to treating HCV infection in PWIDs because PWIDs are often accompanied by concurrent infection, low compliance, substance abuse, and risky behavior. The aim of the study is to compare the efficacies of direct-acting antiviral (DAA) therapy for HCV infection in PWIDs and those without opioid injection. Materials and Methods: In this retrospective cohort study, we included 53 PWIDs with HCV infections treated on site in a methadone program and 106 age- and sex-matched patients with HCV infections who had no history of opioid injection (ratio of 1:2). All eligible subjects received anti-HCV treatment by DAA agents in our hospital from March 2018 to December 2020. The charts of these patients were carefully reviewed for demographic data, types of DAA agents, and treatment outcomes. The primary outcome measure was sustained virological response (SVR). Results: PWIDs and non-drug users had different HCV genotype profiles (p = 0.013). The former had higher proportions of genotype 3 (18.9% vs. 7.5%) and genotype 6 (24.5% vs. 14.2%) than the latter. The two patient groups had comparable rates of complete drug refilling (100.0% vs. 91.1%) and frequency of loss to follow-up (3.8% vs. 0.9%). However, PWIDs had a lower SVR rate of DAA treatment than non-drug users (92.2% vs. 99.0%; p = 0.04). Further analysis showed that both human immunodeficiency virus (HIV) coinfection and history of PWID were risk factors associated with treatment failure. The subjects with coinfection with HIV had lower SVR rates than those without HIV infection (50.0% vs. 96.5%; p = 0.021). Conclusions: PWIDs with HCV infections have higher proportions of HCV genotype 3 and genotype 6 than non-drug users with infections. DAA therapy can achieve a high cure rate (>90%) for HCV infection in PWID, but its efficacy in PWID is lower than that in non-drug users.
format Online
Article
Text
id pubmed-8950806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89508062022-03-26 Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users Hsu, Jui-Ting Hsu, Ping-I Shie, Chang-Bih Chuah, Seng-Kee Wu, I-Ting Huang, Wen-Wei Tang, Sheng-Yeh Tsai, Kun-Feng Kuo, Li-Fu Ghose, Supratip Hsu, Jui-Che Shih, Chih-An Medicina (Kaunas) Article Background and Objectives: Hepatitis C virus (HCV) is a major cause of liver disease worldwide. People who inject drugs (PWIDs) constitute the majority of patients with HCV infection in the United States and Central Asia. There are several obstacles to treating HCV infection in PWIDs because PWIDs are often accompanied by concurrent infection, low compliance, substance abuse, and risky behavior. The aim of the study is to compare the efficacies of direct-acting antiviral (DAA) therapy for HCV infection in PWIDs and those without opioid injection. Materials and Methods: In this retrospective cohort study, we included 53 PWIDs with HCV infections treated on site in a methadone program and 106 age- and sex-matched patients with HCV infections who had no history of opioid injection (ratio of 1:2). All eligible subjects received anti-HCV treatment by DAA agents in our hospital from March 2018 to December 2020. The charts of these patients were carefully reviewed for demographic data, types of DAA agents, and treatment outcomes. The primary outcome measure was sustained virological response (SVR). Results: PWIDs and non-drug users had different HCV genotype profiles (p = 0.013). The former had higher proportions of genotype 3 (18.9% vs. 7.5%) and genotype 6 (24.5% vs. 14.2%) than the latter. The two patient groups had comparable rates of complete drug refilling (100.0% vs. 91.1%) and frequency of loss to follow-up (3.8% vs. 0.9%). However, PWIDs had a lower SVR rate of DAA treatment than non-drug users (92.2% vs. 99.0%; p = 0.04). Further analysis showed that both human immunodeficiency virus (HIV) coinfection and history of PWID were risk factors associated with treatment failure. The subjects with coinfection with HIV had lower SVR rates than those without HIV infection (50.0% vs. 96.5%; p = 0.021). Conclusions: PWIDs with HCV infections have higher proportions of HCV genotype 3 and genotype 6 than non-drug users with infections. DAA therapy can achieve a high cure rate (>90%) for HCV infection in PWID, but its efficacy in PWID is lower than that in non-drug users. MDPI 2022-03-17 /pmc/articles/PMC8950806/ /pubmed/35334612 http://dx.doi.org/10.3390/medicina58030436 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hsu, Jui-Ting
Hsu, Ping-I
Shie, Chang-Bih
Chuah, Seng-Kee
Wu, I-Ting
Huang, Wen-Wei
Tang, Sheng-Yeh
Tsai, Kun-Feng
Kuo, Li-Fu
Ghose, Supratip
Hsu, Jui-Che
Shih, Chih-An
Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
title Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
title_full Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
title_fullStr Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
title_full_unstemmed Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
title_short Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
title_sort comparison of the efficacies of direct-acting antiviral treatment for hcv infection in people who inject drugs and non-drug users
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950806/
https://www.ncbi.nlm.nih.gov/pubmed/35334612
http://dx.doi.org/10.3390/medicina58030436
work_keys_str_mv AT hsujuiting comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT hsupingi comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT shiechangbih comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT chuahsengkee comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT wuiting comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT huangwenwei comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT tangshengyeh comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT tsaikunfeng comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT kuolifu comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT ghosesupratip comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT hsujuiche comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers
AT shihchihan comparisonoftheefficaciesofdirectactingantiviraltreatmentforhcvinfectioninpeoplewhoinjectdrugsandnondrugusers